BrightAccountsProduction v1.0.0 v1.0.0 2024-07-01 The company was not dormant during the period The company was trading for the entire period Unaudited Accounts FRS 105 Accounts Research and experimental development on biotechnology. 13 January 2026 2 2 NI662211 2025-06-30 NI662211 2024-06-30 NI662211 2023-06-30 NI662211 2024-07-01 2025-06-30 NI662211 2023-07-01 2024-06-30 NI662211 uk-bus:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 NI662211 uk-curr:PoundSterling 2024-07-01 2025-06-30 NI662211 uk-bus:AbridgedAccounts 2024-07-01 2025-06-30 NI662211 uk-core:CapitalReserve 2025-06-30 NI662211 uk-core:CapitalReserve 2024-06-30 NI662211 2024-07-01 2025-06-30 NI662211 uk-bus:Director1 2024-07-01 2025-06-30 NI662211 uk-bus:AuditExempt-NoAccountantsReport 2024-07-01 2025-06-30 NI662211 uk-bus:Micro-entities 2024-07-01 2025-06-30 xbrli:pure iso4217:GBP xbrli:shares
 
 
 
Eyeomics Limited
 
Unaudited Financial Statements
 
for the financial year ended 30 June 2025



Eyeomics Limited
Company Registration Number: NI662211
STATEMENT OF FINANCIAL POSITION
as at 30 June 2025

    2025   2024
  £   £
 
Creditors: amounts falling due within one year (11,686)   (11,686)
  ─────────   ─────────
Total Assets less Current Liabilities (11,686)   (11,686)
Accruals and deferred income (165)   (165)
  ─────────   ─────────
Net Liabilities (11,851)   (11,851)
  ═════════   ═════════
 
Capital and Reserves (11,851)   (11,851)
  ═════════   ═════════
 
Notes to the Financial statements
   
1. General Information
 

Eyeomics Limited is a company limited by shares incorporated and registered in Northern Ireland. The registered number of the company is NI662211. The registered office of the company is 16 Mount Charles, Belfast, BT7 1NZ. The financial statements have been presented in Pound (£) which is also the functional currency of the company.
   
2. Going concern
 
The company made no profit or loss to 30th June 2025 (2024: £350 loss) and has negative shareholders' funds of £11,851 (2024: £11,851). The directors have agreed not to withdraw their support within 12 months of the date of signature of the financial statements. The directors therefore consider it appropriate to prepare the financial statements on the going concern basis. The financial statements do not include any adjustments that would result from the support outlined being withdrawn.
       
3. Employees
 
The average monthly number of employees, including directors, during the financial year was;
 
  2025 2024
  Number Number
 
Directors 2 2
  ═════════ ═════════
   
4. Post-Balance Sheet Events
 
There have been no significant events affecting the company since the financial year-end.
     
For the financial year ended 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006.
 
The directors confirm that the members have not required the company to obtain an audit of its financial statements for the financial year in question in accordance with section 476 of the Companies Act 2006.
 
The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit and loss for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
 
These financial statements have been prepared in accordance with the provisions available to micro-entities in Part 15 of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
 
The company has taken advantage of the exemption under section 444 not to file the Income Statement.
 
Approved by the Board on 13 January 2026 and signed on its behalf by:
 
   
________________________________  
Prof. Jonathan Moore  
Director